HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: A case report

Cases Journal

Volumn 1, Issue 1, 2008, Pages

  Pandey, Krishna ^a   Sinha, Prabhat Kumar ^a   Rabidas, Vidya ^a   Kumar, Nawin ^a   Bimal, Sanjiva ^a   Verma, Neena ^a   Lal, Chandrasekhar ^a   Das, Pradeep ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; CARBIDOPA; ENTACAPONE; FOLIC ACID; IRON; LAMIVUDINE; LEVODOPA; MILTEFOSINE; NEVIRAPINE; SELEGILINE; TRIHEXYPHENIDYL; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIABETIC DIET; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERURICEMIA; MALE; MIDDLE AGED; MIXED INFECTION; PARKINSONISM; URIC ACID BLOOD LEVEL; VISCERAL LEISHMANIASIS; WESTERN BLOTTING;

EID: 84877739579     PISSN: 17571626     EISSN: 17571626     Source Type: Journal    
DOI: 10.1186/1757-1626-1-183     Document Type: Article

References (12)

1. Desjeux P, Meert JP, Piot B, et al.: Leishmania/HIV co-infection in south-western Europe 1990-1998. Document WHO/LEISH/ 2000.42. Geneva: World Health Organization; 2000.
2. Guerin PJ, Olliaro P, Sundar S, et al.: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Diseases 2002, 2:494-501.
3. Bhattacharya SK, Sur D, Sinha PK, Karbwang J: Elimination of Leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. Indian Journal of Medical Research 2006, 123:195-196.
4. UNAIDS: AIDS Epidemic Update. 2007.
5. Pandey K, Sinha PK, Das VN, et al.: HIV-1 infection, visceral leishmaniasis, Koch's chest and tuberculous meningitis in the same patient - a case report. Annals of Tropical Medicine & Parasitology 2005, 99:807-811.
6. Das VN, Ranjan A, Bimal S, et al.: Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. National Medical Journal of India 2005, 18:131-133.
7. Bhattacharya SK, Jha TK, Sundar S, et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clinical Infectious Diseases 2004, 38:217-221.
8. Bhattacharya SK, Sinha PK, Sundar S, et al.: Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. Journal of Infectious Diseases 2007, 196:591-598.
9. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK: Injectable Paromomycin for Visceral Leishmaniasis in India. The New England Journal of Medicine 2007, 356:2571-2581.
10. Agrawal S, Rai M, Sundar S: Management of visceral leishmaniasis: Indian perspective. J Postgrad Med 2005, 51(Suppl 1):S53-S57.
11. Tse W, Cersosimo MG, Gracies JM, et al.: Movement disorders and AIDS: a review. Parkinsonism Related Disorders 2004, 10:323-334.
12. Kelly DV, Beique LC, Bowmer MI: Extrapyramidal symptoms with ritonavir/indianvir plus risperidone. Annals of Pharmacotherapy 2002, 36:827-830.